Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Rossi
D
D
Catalano
G
G
D000284:Administration, Oral; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives*; D004890:Erythema / Q000139:chemically induced / Q000517:prevention & control*; D005533:Foot Dermatoses / Q000139:chemically induced / Q000517:prevention & control; D006229:Hand Dermatoses / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D010292:Paresthesia / Q000139:chemically induced / Q000517:prevention & control*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011736:Pyridoxine / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D011736:Pyridoxine